Merck & Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of the year, accelerating the company’s efforts to protect its top ...

with the German firm’s Merck Serono division licensing various technologies used to engineer T-cells to target cancers, including its RheoSwitch platform for controlling gene expression and ...

Rumours that Merck was planning a $30 billion-plus takeover bid for Seagen have so far come to nothing, but it did complete a deal to buy VelosBio for $2.75 billion in late 2020 to add an ADC ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...